AIM 001
Alternative Names: AdAPT-001; AIM-001; Multi-vax TGF-beta trap transgene expressing oncolytic smart virus; TGF- Trap Adenovirus; TGF-beta trap - EpicentRxLatest Information Update: 04 Jul 2025
At a glance
- Originator EpicentRx
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunostimulants; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 25 Apr 2025 Efficacy data from a phase I/II trial in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamics data from a pre-clinical trial in Sarcoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 05 Dec 2024 AIM 001 receives Fast track status from the US FDA for Soft tissue sarcoma (Combination therapy Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater)